covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Aportaciones de la medicina nuclear al diagnóstico y seguimiento de los tumores...
Journal Information
Vol. 56. Issue S3.
Aspectos Diagnósticos de los Tumores Neuroendocrinos
Pages 14-19 (September 2009)
Share
Share
Download PDF
More article options
Vol. 56. Issue S3.
Aspectos Diagnósticos de los Tumores Neuroendocrinos
Pages 14-19 (September 2009)
Full text access
Aportaciones de la medicina nuclear al diagnóstico y seguimiento de los tumores neuroendocrinos gastroenteropancreáticos
Contributions of nuclear medicine to the diagnosis and follow-up of gastroenteropancreatic neuroendocrine tumors
Visits
7415
Mercedes Mitjavila Casanovas
Corresponding author
mmitjavila@fhalcorcon.es

Correspondencia: Departamento de Imagen, Medicina Nuclear. Hospital Universitario Fundación Alcorcón. Budapest, 1. 28922 Alcorcón. Madrid. España.
Departamento de Imagen, Medicina Nuclear. Hospital Universitario Fundación Alcorcón. Alcorcón. Madrid. España
This item has received
Article information

El tratamiento óptimo de los pacientes con tumores neuroendocrinos gastroenteropancreáticos requiere una adecuada estadificación de los pacientes. La medicina nuclear es una técnica de imagen que aporta una información funcional. En los tumores neuroendocrinos gastroenteropancreáticos dicha información se obtiene con la utilización de radiotrazadores que aportan información sobre la síntesis de aminas (MIBG) y/o expresión de receptores de somatostatina (111-In-octreotido, 68galio-DOTATOC) por la célula tumoral, tanto del tumor primario como sus metástasis. La experiencia acumulada demuestra que las técnicas de medicina nuclear son una herramienta fundamental en el manejo de estos pacientes. Se revisan las indicaciones en el diagnóstico, estudio de extensión y seguimiento de estos tumores con los diferentes radiotrazadores disponibles.

Palabras clave:
Tumores neuroendocrinos gastroenteropancreáticos
Meta-iodobencilguanidina
111-In-octreotido
Tomografía por emisión de positrones

The optimal treatment of patients with gastroenteropancreatic neuroendocrine tumors requires accurate staging. Nuclear medicine is an imaging technique that provides functional information. In gastroenteropancreatic neuroendocrine tumors this information is obtained from radiotracers providing data on amine synthesis (MIBG) and/or somatostatin receptor expression (111-In-octreotide, 68Galio-DOTATOC) by the tumoral cell, both in primary and metastatic tumors. The accumulated experience shows that nuclear medicine techniques are essential in the management of these patients. The indications in the diagnosis, extension study and follow-up of these tumors, as well as the distinct radiotracers available, are reviewed.

Key words:
Gastroenteropancreatic neuroendocrine tumors
MIBG
111-In-octreotide
PET
Full text is only aviable in PDF
Bibliografía
[1.]
A. Sundin, U. Garske, H. Örlefors.
Nuclear imaging of neuroendocrine tumours.
Best Practice Research Clinical Endocrinol Metabolism, 21 (2007), pp. 69-85
[2.]
V. Rufini, M.L. Calcagni, R.P. Baum.
Imaging of neuroendocrine tumors.
Semin Nucl Med, 36 (2006), pp. 228-247
[3.]
M.J. Berna, R.T. Jensen.
Uses of radiolabeled somatostatin receptor analogues in diagnosis of gastrointestinal neuroendocrine tumors.
A Century of advances in neuroendocrine tumor biology and treatment, pp. 328-339
[4.]
C.M. Intenzo, S. Jabbour, H.C. Lin, J.L. Miller, S.M. Kim, D.M. Capuzzi, et al.
Scintigraphic Imaging of body neuroendocrine tumors.
Radiographics, 27 (2007), pp. 1355-1369
[5.]
J. Banzo, E. Prats, P. Razaola, S. García, V. Alonso, J. Velilla, et al.
Atlas de gammagrafía de receptores de somatostatina en tumores neuroendocrinos de páncreas y tumores carcinoides.
Rev Esp Med Nucl, 24 (2005), pp. 278-292
[6.]
N. Alexakis, J.P. Neoptolemos.
Pancreatic neuroendocrine tumours.
Best practice Resaerch Clicical Gastroenterol, 22 (2008), pp. 183-205
[7.]
M.T. Barakat, K. Meeran, S.R. Bloom.
Neuroendocrine tumors.
Endocrine-Related Cancer, 11 (2004), pp. 1-18
[8.]
Öberg K. Eriksson.
Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
Best Practice Research Clinical Endocrinol Metabolism, 19 (2005), pp. 265-276
[9.]
O. Schillaci, A. Sapnu, F. Scopinaro, A. Falchi, R. Danieli, P. Marongiu, et al.
Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
J Nucl Med, 44 (2003), pp. 359-368
[10.]
T. Steinmüller, R. Kianmanesh, M. Falconi, A. Scarpa, B. Taal, Kwekkeboom., et al.
Consensus guideline for the management of patients with liver metastases from digestive (Neuro)endocrine tumors: Foregut, midgut, hindgut, and unknown primary.
Neuroendocrinology, 87 (2008), pp. 47-62
[11.]
D. Metz, R.T. Jensen.
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.
Gastroenterology, 135 (2008), pp. 1469-1492
[12.]
R. Sutcliffe, D. Maguire, J. Ramage, M. Rela, N. Heaton.
Management of neuroendocrine liver metastases.
Am J Surg, 187 (2004), pp. 39-46
[13.]
H. Amthauer, J. Ruf, M. Böhmig, E. López-Hännien, T. Rohlfing, K.D. Wernecke, et al.
Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?.
Eur J Nucl Med Mol Imaging, 31 (2004), pp. 342-348
[14.]
C.J. Ingui, N.P. Shah, E. Oates.
Endocrine neoplasm scintigraphy added value of fusing SPECT/CT images compared with traditional side-by-side analysis.
Clin Nucl Med, 31 (2006), pp. 665-672
[15.]
J. Arbizu, M. Rodríguez-Fraile, I. Domínguez-Prado, P. Garrastachu, F. Rotellar, B. Sangro, et al.
Whole body 18-fluoro-L-DOPA PET-CT: an useful tool for location and surgical guidance in primary carcinoid tumours.
Eur J Nucl Med Mol Imaging, 35 (2008), pp. 1577
[16.]
S. Adams, R. Baum, A. Hertel, H.JC. Wenish, E. Staib-Sebler, G. Hermann, et al.
Intraoperative gammaprobe detection of neuroendocrine tumors.
J Nucl Med, 39 (1998), pp. 1155-1160
[17.]
Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, et al. 111In-Pentetreotide Scintigraphy - Procedure Guidelines For Tumour Imaging. Disponible en: https://www.eanm.org/scientific_info/guidelines/
[18.]
A. Becherer, M. Szabó, G. Karanikas, P. Wunderbaldinger, P. Angelberger, M. Raderer, et al.
Imaging of advanced neuroendocrine tumors with 18F-FDOPA-PET.
J Nucl Med, 45 (2004), pp. 1161-1167
[19.]
M.U. Khan, S. Khan, S. El-Refaie, Z. Win, D. Rubello, A. Al-Nahhas.
Clinical indications for Gallium-68 positron emission tomography imaging.
Eur J Sur Oncol, (2009),
[20.]
I. Buchmann, M. Henze, S. Engelbrecht, M. Eisenhut, A. Runz, M. Schäfer, et al.
Comparison of 68Ga-DOTATO PET and 111In-DTPAOC (octreoscan) SPECT in patinets with neuroendocrine tumor.
Eur J Nucl Med Mol Imaging, 34 (2007), pp. 1617-1626
Copyright © 2009. Sociedad Española de Endocrinología y Nutrición
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos